

Article



# Iron Transport from Ferrous Bisglycinate and Ferrous Sulfate in DMT1-Knockout Human Intestinal Caco-2 Cells

## Xiaonan Yu, Lingjun Chen, Haoxuan Ding, Yang Zhao and Jie Feng \*

Key Laboratory of Animal Nutrition & Feed Science, Zhejiang Province, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China; 21617026@zju.edu.cn (X.Y.); 21717018@zju.edu.cn (L.C.); 11717014@zju.edu.cn (H.D.); 21817006@zju.edu.cn (Y.Z.)

\* Correspondence: fengj@zju.edu.cn; Tel.: +86-571-8898-2121

Received: 2 January 2019; Accepted: 21 February 2019; Published: 26 February 2019



**Abstract:** This experiment was conducted to investigate the transport characteristics of iron from ferrous bisglycinate (Fe-Gly) in intestinal cells. The divalent metal transporter 1 (DMT1)-knockout Caco-2 cell line was developed by Crispr-Cas9, and then the cells were treated with ferrous sulfate (FeSO<sub>4</sub>) or Fe-Gly to observe the labile iron pool and determine their iron transport. The results showed that the intracellular labile iron increased significantly with Fe-Gly or FeSO<sub>4</sub> treatment, and this phenomenon was evident over a wide range of time and iron concentrations in the wild-type cells, whereas in the knockout cells it increased only after processing with high concentrations of iron for a long time (p < 0.05). DMT1-knockout suppressed the synthesis of ferritin and inhibited the response of iron regulatory protein 1 (IRP-1) and IRP-2 to these two iron sources. The expression of peptide transporter 1 (PepT1) was not altered by knockout or iron treatment. Interestingly, the expression of zinc-regulated transporter (ZRT) and iron-regulated transporter (IRT)-like protein 14 (Zip14) was elevated significantly by knockout and iron treatment in wild-type cells (p < 0.05). These results indicated that iron from Fe-Gly was probably mainly transported into enterocytes via DMT1 like FeSO<sub>4</sub>; Zip14 may play a certain role in the intestinal iron transport.

Keywords: DMT1; knockout; ferrous bisglycinate; ferrous sulfate; transport; intestinal

## 1. Introduction

Iron is one of the essential trace elements and a cofactor for various enzymes. It is involved in many important physiological processes, such as oxygen transport, electron transport, tricarboxylic acid cycle, and hemoglobin and myoglobin production. Iron deficiency can induce anemia and affects cell metabolism [1–3]. Taking into account the vital functions of iron, exogenous iron is often supplemented as food fortification and feed additive to human and animals to prevent iron deficiency [4–6]. However, due to the low bioavailability of inorganic iron, it often causes mineral resources waste and environmental pollution, and its abuse also affects human health and animal production [7–9].

The use of more efficient sources of iron is a strategy to alleviate the problems caused by excess inorganic iron. Recent studies have shown that amino acid chelated iron sources such as Fe-Gly have better iron bioavailability than inorganic iron sources such as  $FeSO_4$  [10–13]. The high bioavailability of amino acid chelated iron may be related to its efficient absorption and transport mechanism. However, at present, its intestinal absorption and transport mechanisms are still unclear, since there were few studies on this aspect. Some researchers thought that amino acid chelated iron might be transported across the brush border membrane (BBM) as a whole by the peptide transporter 1

(PepT1), similar to the intestinal absorption of small peptides. Their studies have shown that the intestinal uptake of amino acid chelated iron was in greater amounts and more rapid than equivalent quantities of iron salts. Furthermore, compared with FeSO<sub>4</sub>, Fe-Gly has been shown to significantly increase PepT1 mRNA level and protein expression in the small intestinal epithelium cells (IPEC-1) of pigs [14,15]. Others thought that amino acid chelated iron was absorbed by the enterocytes in the same manner as inorganic iron. Researchers have demonstrated that iron from the Fe-Gly competed with FeSO<sub>4</sub> for the nonheme-iron absorption pathway [16]. Fe-Gly and FeSO<sub>4</sub> had similar absorption kinetics characteristics and their intestinal absorptions were significantly inhibited by divalent metal ions [17,18]. In our previous study, the duodenum of Sprague–Dawley (SD) rats given Fe-Gly or FeSO<sub>4</sub> were collected for transcriptome sequencing. The results showed that there was no significant difference in the expression of any iron transporter in the duodenum of rats administrated with Fe-Gly or FeSO<sub>4</sub>, suggesting that the amino acid chelated iron may be absorbed by the intestine in the same manner as inorganic iron, which was mainly transported into the intestinal cells via the divalent metal ion transporter DMT1 [19].

DMT1 is a key mammalian iron transporter in the enterocytes, and it is selective for the ferrous iron [20,21]. Inorganic dietary iron exists in ferric iron form predominantly; it must first be reduced by duodenal cytochrome B (DcytB) and then enters the enterocytes via DMT1 located in the apical membrane of enterocytes [22–24].

To study the iron transport from Fe-Gly in the intestinal cells, in the present study, we developed a DMT1-knockout Caco-2 cell line by using Crispr-Cas9 and treated the cells with Fe-Gly and FeSO<sub>4</sub> to measure the changes of labile iron pool, ferritin content, and expression of iron regulators and transporters.

### 2. Materials and Methods

## 2.1. Cell Culture

Human Caco-2 cells (HTB-37) were obtained from American Type Culture Collection. Cells were cultured in 25-cm<sup>2</sup> flasks in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, NYC, USA) with 10% fetal bovine serum (Gibco, NYC, USA), 100 U/mL penicillin-streptomycin (Gibco, NYC, USA) and 1% non-essential amino acids (Gibco, NYC, USA) and were incubated at 37 °C, 5% CO<sub>2</sub>. Monolayers were grown by seeding Caco-2 cells (passage 20–40) at a density of  $1 \times 10^4$  cells/cm<sup>2</sup> in 6-well plates or 96-well plates for about 14 days, with media changed every 2 days.

## 2.2. Knockout of DMT1 in Caco-2 Cells by Using Crispr Cas9

To generate CRISPR knockout cells, Caco-2 cells were transfected with plasmids expressing Cas9, Puro, Amp, and sgRNA for DMT1 and grown for 72 h. The sgRNAs used included 5'-AGAGAGGGATTACTATAGGCAGG-3', 5'-CATGGGGGAGTCTGCCAGTCTTGG-3', and 5'-GAA GATCTCCATTCCTGAGGAGG-3', which were designed based on the first exon of the public coding sequence (CDS) region located in all transcripts of DMT1. After that, the cells were screened by puromycin and separated as single cells into 96-well plates. After 2 weeks, the colonies were transferred to 48-well plates for expansion. After the cells were covered with 48-well plates, a portion  $(10^2-10^4)$  was removed and the Genloci TNA extraction kit (Genloci Biotechnologies Inc., Nanjing, China) was used to extract the cell genome. The following reaction system was prepared in a sterile Polymerase Chain Reaction (PCR) tube to amplify wild-type and mutant-type sufficiently hybridized DNA products. A pair of highly specific primers were designed near the knockout target site and the amplified product was approximately 316 bp in length. Primer sequences were as follows: 5'-GTATACTAAGGATGAATTGT-3', 3'-AACCTGAGGCTGCTGAACTT-5'. The procedure used in the polymerase chain reaction (PCR) program was an initial denaturation (1.5 min at 95 °C), a three-step amplification program (10 s at 95 °C, 10 s at 62 °C, and 20 s at 72 °C) that was repeated 40 times, a complete extension (5 min at 95 °C) and a final denaturation (3 min at 72 °C). The amplified products were initially screened by the Cruiser<sup>TM</sup>

Enzyme (Genloci Biotechnologies Inc., Nanjing, China) to obtain positive clones, and then the clones were further verified by sequencing and western blot analysis.

#### 2.3. Measurement of Cell Viability

Wild-type and DMT1 knockout Caco-2 cells were seeded at a density of  $1 \times 10^4$  cells/cm<sup>2</sup> in 96-well plates. After 14 days, the medium was discarded and the cells were washed twice with PBS and then incubated with DMEM containing 100  $\mu$ M deferoxamine (DFO) (Sigma, St. Louis, MO, USA). Twenty-four hours later, the medium was discarded and the cells were rinsed twice with PBS before being treated with DMEM containing different concentrations of Fe-Gly and FeSO<sub>4</sub> (0, 25, 50, 100, 200  $\mu$ M). Two hours later, the medium was discarded and the cell viability was assessed by Cell Counting Kit-8 (MedChem Express, Princeton, NJ, USA).

## 2.4. Measurement of Labile Iron with Phen Green SK in Wild-Type and DMT1 Knockout Caco-2 Cells

Wild-type and DMT1 knockout Caco-2 cells were seeded at a density of  $1 \times 10^4$  cells/cm<sup>2</sup> in 96-well plates. After 14 days, the medium was discarded and the cells were washed twice with PBS and then incubated with DMEM containing 100 µM DFO. Twenty-four hours later, the medium was discarded, and the cells were rinsed twice with PBS before being treated with DMEM containing different concentrations (0, 25, 50, 100, 200 µM) of Fe-Gly (Dibo Biotechnology Co., Ltd., Shanghai, China) and FeSO<sub>4</sub> (Sigma, St. Louis, MO, USA). The cells were incubated for 0, 0.5, 1, 2 h and then rinsed twice with PBS and stained with PBS containing 10 µM Phen Green SK (Thermo Fisher P14313) for 1 h at 37 °C. After staining, cells were rinsed with PBS twice and labile iron was measured by using a fluorescence microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA) at an excitation wavelength of 490 nm and an emission wavelength of 520 nm.

## 2.5. Live Fluorescence Imaging of Labile Iron in Wild-Type and DMT1 Knockout Caco-2 Cells

To visualize labile iron, microscopy imaging of the fluorescent dye Phen Green SK (Invitrogen, Eugene, OR, USA) was performed. Wild-type and DMT1 knockout Caco-2 cells were seeded at a density of  $1 \times 10^4$  cells/cm<sup>2</sup> in 6-well plates. After 14 days, the medium was discarded and the cells were washed twice with PBS and then incubated with DMEM containing 100  $\mu$ M DFO. Twenty-four hours later, the medium was discarded and the cells were rinsed twice with PBS before being treated with DMEM containing different concentrations of Fe-Gly and FeSO<sub>4</sub> (0, 25, 50, 100, 200  $\mu$ M). The cells were incubated for an additional 2 h, then rinsed twice with PBS and stained with PBS containing 10  $\mu$ M Phen Green SK for 1 h at 37 °C. Next, the stained cells were rinsed with PBS and observed with a fluorescence microscope (IX7, Olympus Corporation, Tokyo, Japan).

#### 2.6. Western Blot Analysis

After wild-type and DMT1 knockout Caco-2 cells in the 6-well plates were pretreated with DFO as described above, the cells were rinsed twice with PBS and then treated with DMEM containing 0 or 25  $\mu$ M Fe-Gly or FeSO<sub>4</sub> for 2 h. Then cells were lysed with ice-cold radio immunoprecipitation assay (RIPA) buffer (Beyotime Biotechnology, Shanghai, China) containing protease inhibitors and phenylmethanesulfonyl fluoride (PMSF, Beyotime Biotechnology, Shanghai, China) for about 1 min on ice. The lysates were transferred to a 1.5-mL centrifuge tube and were centrifuged at 11,000 × *g* for 10 min at 4 °C, then the supernatants were collected to determine the total protein concentrations using a BCA Protein Assay kit (Keygen biotech. Co. Ltd., Nanjing, China). Next, 5X dual color protein loading buffer (FD bioscience, Hangzhou, China) was added to the supernatant and then the samples were boiled for protein extraction. The extracted proteins (20–40  $\mu$ g) were separated by electrophoresis on a 10% SDS-PAGE gel and transferred onto an activated polyvinylidene fluoride (PVDF) membrane (GE Healthcare Life science, Germany). Subsequently, the membrane was blocked in 5% non-fat milk at room temperature for 1 or 2 h and then incubated overnight at 4 °C with the following primary antibodies and dilution rates: DMT1, 1:500 (Santa Cruz Biotechnology, code sc-166884, Santa Cruz, CA,

USA); Ferritin, 1:1000 (Abcam, code ab75973, Cambridge, UK); iron regulatory protein 1 (IRP-1), 1:1000 (Abcam, code ab126595, Cambridge, UK); IRP-2, 1:400 (Proteintech Group, code23829-1-AP, Chicago, IL, USA); hypoxia-induced factor- $2\alpha$  (HIF- $2\alpha$ ), 1:1000 (Abcam, code ab207607, Cambridge, UK); PepT1, 1:200 (Abcam, code ab123314, Cambridge, UK); ferroportin 1 (FPN1), 1:2000 (Proteintech Group, code 26601-1-AP, Chicago, IL, USA); iron-regulated transporter (IRT)-like protein 14 (Zip14), 1:500 (Abcam, code ab106568, Cambridge, UK); and  $\beta$ -Actin, 1:2000 (Bioker biotechnology, code BK-7018, Hangzhou, China). Then the membrane was rinsed for 10 min three times thoroughly with TBST before incubation with secondary antibody consisting of goat anti-rabbit (1:20,000, Bioler biotechnology, code BK-R050) and goat anti-mouse (1:20,000, Bioker biotechnology, code BK-M050, Hangzhou, China) at room temperature for about 2 h. After that, the membrane was thoroughly rinsed with TBST for 10 min three times. The signals were detected after the addition of ECL Star Chemiluminescence solution according to the manufacturer's instructions (Beyotime Biotechnology, Shanghai, China).

## 2.7. Statistical Analysis

All data are presented as the means or weighted means  $\pm$  SEM of a minimum of three biological replicates unless otherwise noted. Means between groups were compared by one-way analysis of variance and post-hoc Tukey test or non-parameter Kruskal-Wallis test (SPSS software, version 21, SPSS Inc., Chicago, IL, USA) where appropriate. For this study, *p* < 0.05 was considered significant.

## 3. Results

# 3.1. Knockout of DMT1 in Caco-2 Cells by Using Crispr Cas9

To verify the targeted disruption of DMT1 in Caco-2 cells by the Crispr-Cas9 system, we analyzed genomic DNA isolated from transfected cells using Cruiser<sup>TM</sup> Enzyme assay. A 316-base pair (bp) sequence flanking the target site treated by sgRNA-encoded plasmids was amplified by PCR. As expected, the lengths of the PCR products were obviously shorter in mutant cell clones (Figure 1A). Sequencing analysis of the PCR products of these clones revealed that the mutant cells showed 85-bp deletions (5'-TATAGTAATCCCTCTCTTTCACAGTCCCCTGGGGACTCAGAGGAGTACTTCGCCAC TTACTTTAATGAGAAGATCTCCATTCCTG-3') on the exon from the DMT1 gene (Figure 1B–D). Therefore, the mutant was a positive knockout cell line on the genome. We further verified the DMT1 mutation on protein expression level. Western blot results (Figure 1E) showed that there was almost no protein expression of DMT1 in #30–125, which confirmed that the DMT1 knockout Caco-2 cell line was successfully developed.



Figure 1. Cont.



**Figure 1.** Validation of DMT1-knockout Caco-2 cell line. (**A**) The electrophoresis results of the target fragments of DMT1 in the transfected cells; (**B**) Partial sequencing results of the target fragment on DMT1 of wild-type Caco-2 cells; (**C**) Partial sequencing results of the target fragment on DMT1 of the mutant cells; (**D**) Sequence comparison of the target fragment of DMT1 in the mutant and wild-type Caco-2 cells; (**E**) Western blot results of DMT1 in wild-type Caco-2 cells and the mutant cells.

## 3.2. Cell Viability after 2 h of Iron Treatment

As shown in Figure 2, the treatment of FeSO<sub>4</sub> or Fe-Gly at concentration from 25  $\mu$ M to 200  $\mu$ M for 2 h did not affect the viability of wild-type and DMT1 knockout Caco-2 cells.



**Figure 2.** WT: wild-type Caco-2 cell; KO: DMT1-knockout Caco-2 cell. Cell viability of (**A**) wild-type and (**B**) DMT1-knockout Caco-2 cells after 2 h of iron treatment.

## 3.3. Changes of Labile Iron after Treatment with Different Iron Sources

The relative labile iron level was determined by using the turn-off probe Phen Green SK, which was quenched upon intracellular iron binding. After treatment with  $FeSO_4$  and Fe-Gly at different concentrations, the labile iron levels of wild-type Caco-2 cells and DMT1 knockout Caco-2 cells were recorded, as shown in Figure 3.



**Figure 3.** Changes of labile iron after treatment with different iron sources (0, 25, 50, 100, 200  $\mu$ M) in wild-type cells and DMT1-knockout cells. Values not sharing a common letter differ significantly (*p* < 0.05). WT: wild-type Caco-2 cell; KO: DMT1-knockout Caco-2 cell; RFU: relative florescence unit. Changes of labile iron after 0.5 h (**A**,**B**), 1 h (**C**,**D**), 2 h (**E**,**F**) treatment with different iron sources in wild-type cells and DMT1-knockout cells.

After 30 min, 200  $\mu$ M FeSO<sub>4</sub> or Fe-Gly lead to significant Phen Green SK quenching in the wild-type Caco-2 cells (p = 0.000301, p = 0.000319), which indicated the significant increase of labile iron, whereas the treatment of iron had no effect on it in the knockout cells (Figure 3A,B). An hour later, the labile iron level of wild-type cells began to increase when the concentration of FeSO<sub>4</sub> or Fe-Gly reached 100  $\mu$ M (p < 0.05), while there was no change in it in the knockout cells (Figure 3C,D). Figure 3E,F show that there was a significant increase in the labile iron level in wild-type cells after

treatment with 25, 50, 100, 200  $\mu$ M FeSO<sub>4</sub> or Fe-Gly for two hours, while that in the knockout cells elevated after processing with 100 and 200  $\mu$ M iron (*p* < 0.05).

## 3.4. Live Cell Fluorescence Imaging of Labile Iron with Phen Green SK

To visualize labile iron, cells on a 6-well plate were stained with Phen Green-SK and observed by a fluorescence microscopy. The cells were treated with gradient concentrations of iron for 2 h based on the results above. It can be seen from Figure 4A,B that low concentrations of Fe-Gly or FeSO<sub>4</sub> result in the quenching of Phen Green SK in the wild-type cells, which indicates the increase of labile iron, while that in the knockout cells began to change after processing with higher concentrations of iron. The results of the live cell fluorescence imaging of labile iron confirmed the results we obtained by the fluorescence microplate reader.



**Figure 4.** Live cell fluorescence imaging (200x) of labile iron in wild-type cells and DMT1-knockout cells after treated with different concentrations of  $FeSO_4$  and Fe-Gly for two hours. (A) Fluorescence imaging of labile iron in wild-type cells; (B) Fluorescence imaging of labile iron in DMT1-knockout cells.

## 3.5. Expression of Iron Regulators and Transporters

The protein expression levels of the iron regulators and transporters were measured after cells were treated with 25  $\mu$ M Fe-Gly or FeSO<sub>4</sub> for 2 h and normalized to  $\beta$ -actin. Obviously increased expression of HIF-2 $\alpha$ , IRP-1, and IRP-2 and decreased content of ferritin was observed after DMT1-knockout in Caco-2 cells (p < 0.05) (Figure 5). Furthermore, treatment of these two iron sources increased ferritin content and decreased DMT1 expression levels significantly in the wild-type cells, while those regulators in the knockout cells did not respond to the Fe-Gly or FeSO<sub>4</sub> and there was almost no expression of DMT1 in the knockout cells (Figure 5). In the wild-type cells, the expression of IRP-1 was decreased significantly after treatment with FeSO<sub>4</sub> (Figure 5D). Figure 5E,F show that the expression of PepT1 and FPN1 were not altered by knockout or iron treatment. Interestingly, the expression of Zip14 was elevated significantly by knockout and iron treatment in wild-type cells (p < 0.05) and decreased slightly after iron treatment in knockout cells (Figure 5H).



Figure 5. Cont.





**Figure 5.** Expression of some iron regulators and transporters after treated with 25  $\mu$ M of different iron sources for two hours. Values not sharing a common letter differ significantly (p < 0.05). W: wild-type cells treated with 0  $\mu$ M iron; W25S, W25G: wild-type cells treated with 25  $\mu$ M FeSO<sub>4</sub>, 25  $\mu$ M Fe-Gly; K0: DMT1-knockout cells treated with 0  $\mu$ M iron; K25S, K25G: W0: wild-type cells treated with 0  $\mu$ M iron; W25S, W25G: wild-type cells treated with 25  $\mu$ M FeSO<sub>4</sub>, 25  $\mu$ M FeSO<sub>4</sub>, 25  $\mu$ M Fe-Gly; treated with 25  $\mu$ M FeSO<sub>4</sub>, 25  $\mu$ M Fe-Gly; treated with 25  $\mu$ M FeSO<sub>4</sub>, 25  $\mu$ M Fe-Gly. (**A**) Western blot bands of iron regulators and transporters. Statistical analysis of (**B**) hypoxia-induced factor-2 $\alpha$  (HIF-2 $\alpha$ ), (**C**) iron regulatory protein 1 (IRP-1), (**D**) IRP-2, (**E**) peptide transporter 1 (PepT1), (**F**) ferroportin 1 (FPN1), (**G**) DMT1, (**H**) iron-regulated transporter (IRT)-like protein 14 (Zip14), (**I**) ferritin expression.

#### 4. Discussion

The transport characteristics of Fe-Gly in the enterocytes have not been clarified yet. In this study, to further investigate whether iron from Fe-Gly was transported into enterocytes like inorganic iron via DMT1, we developed a DMT1-knockout Caco-2 cell line by using Crispr-Cas9 and treated the cells with Fe-Gly and FeSO<sub>4</sub> to observe the labile iron pool and determine the transport of the two forms of iron. DMT1 is the main transporter of inorganic iron in the intestine. After iron is transported into enterocytes through DMT1, it will first enter the cytosolic pool termed "labile iron pool", which is destined for metabolism, storage, or export [23,24]. The results we obtained by using the turn-off probe Phen Green SK showed that the intracellular labile iron increased significantly with Fe-Gly or FeSO<sub>4</sub> treatment, and this phenomenon was evident over a wide range of time and iron concentrations in the wild-type cells. However, in the knockout cells, the labile iron increased only after processing with high concentrations of iron for a long time (p < 0.05) (Figures 3 and 4). These results indicated that the increase of intracellular labile iron pool after treatment with Fe-Gly or FeSO<sub>4</sub> was inhibited by DMT1 knockout.

Iron from the labile iron pool that is not utilized or exported is stored in a non-toxic form within ferritin [1,2]. In this experiment, knockout of DMT1 decreased ferritin content (p < 0.05), and treatment with 25 µM Fe-Gly or FeSO<sub>4</sub> for 2 h increased its content in the wild-type cells (p < 0.05) but not in the DMT1-knockout cells (Figure 5I). The results indicated that the synthesis of ferritin was suppressed by DMT1 knockout. Since ferritin synthesis reflects intracellular iron bioavailability [2,6], the greater synthesis of ferritin in the wild-type cells suggests that the iron storage and utilization from Fe-Gly were affected by the absence of DMT1 as FeSO<sub>4</sub>.

Cellular iron homeostasis is mainly orchestrated post-transcriptionally by iron regulatory proteins IRP-1 and IRP-2. The two orthologous RNA-binding proteins sense the labile iron pool, and the conversion of IRP-1 to aconitine and degradation of IRP-2 will be promoted upon iron replete [25,26]. In the current study, both IRP-1 and IRP-2 expression were increased due to the absence of DMT1 (p < 0.05), which reflected the lower intracellular iron content in the knockout cells than the wild-type cells. The results also showed that in wild-type cells, the protein expression level of IRP-1 decreased significantly after being treating with FeSO<sub>4</sub> and decreased slightly after being treated with Fe-Gly. The protein expression levels of IRP-2 decreased after treatment with both iron sources, but the difference was not significant. These results indicate the elevation of the intracellular iron levels in the cells. However, in the knockout cells, they were not altered by treatment with either of these two iron sources (Figure 5B,C). These results demonstrated that iron uptake from Fe-Gly and FeSO<sub>4</sub> were suppressed by DMT1 deficiency. IRPs interact with iron regulatory elements (IREs), which are present in the 5' or 3' untranslated regions (UTRs) of target mRNAs. IRP-binding to IREs responds to intracellular iron levels. During iron deficiency, IRPs bind to 5'UTR IRE of mRNAs encoding genes like HIF-2 $\alpha$  and FPN1, thus inhibiting their translation. The IRPs also appear to stimulate the translation of genes like DMT1 when bound to the 3' UTR IRE of their mRNAs [27–31]. In this study, the expression of FPN1 did not change significantly by knockout or iron treatment (Figure 5F). In the current study, the cells were cultured on an ordinary well plate, which may affect the basolateral transport of iron and thus may have affected the regulation of FPN1. In addition, some isoforms of FPN1 mRNA lack IRE and thus escape the IRP regulation [2]. HIF- $2\alpha$  did not respond to iron treatment either, but its expression was significantly increased by DMT1 knockout (p < 0.05) (Figure 5B). In addition to the regulation of the IRP system, HIF-2 $\alpha$  is directly affected by iron content, and it will be degraded after iron-mediated proline hydroxylation. Under these two different regulatory mechanisms, there was a significant increase in HIF-2 $\alpha$  in DMT1-knockout cells [32–34]. It was also observed in this experiment that after treatment with the two iron sources, the expression of DMT1 was significantly decreased in wild-type cells (p < 0.05), while there was almost no expression in knockout cells (Figure 5G). All of the above results indicated that the iron content in the knockout cells was lower than that of the wild-type cells, and the iron absorption of the two iron sources were both affected by the knockout of DMT1.

In addition, we also measured the expression of intestinal peptide transporter PepT1. A previous study reported that Fe-Gly significantly increases PepT1 mRNA level and protein expression in the small intestinal epithelium cells (IPEC-1) of pigs, and the reporter thought that Fe-Gly may be mediated into the intestinal cells via PepT1 [15]. However, in our study, the expression of PepT1 did not differ between wild-type and DMT1-knockout cells and between Fe-Gly and FeSO<sub>4</sub> treatment (Figure 5E). This result was consistent with our previous study, which showed that there was no difference in the expression of PepT1 in the duodenum of rats administrated with Fe-Gly or FeSO<sub>4</sub> [19].

Interestingly, when measuring the labile iron in DMT1 knockout cells, we found that the labile iron could elevate after treating with high concentrations of the two iron sources for a certain period of time. Since DMT1 was almost absent in the knockout cells and did not respond to iron treatment, we suspect that there may be other ways to mediate iron into the intestinal cells, and the transporter may be zinc-regulated transporter (ZRT) or iron-regulated transporter (IRT)-like protein 14 (Zip14). Zip14 was first proven to be a zinc transporter and recent studies have shown that it can mediate the absorption of non-transferrin bound iron (NTBI) in liver and other organs. NTBI appears the when the iron-binding capacity of plasma transferrin is exceeded under iron overload [35–40]. Recently, some studies have reported that it plays an important role in maintaining manganese homeostasis [41–43]. In the current study, we determined the protein expression of Zip14 and we found some interesting results. Knockout of DMT1 significantly increased the expression of Zip14 (p < 0.05). Furthermore, iron treatment significantly promoted Zip14 expression in wild-type cells (p < 0.05), while it slightly inhibited its expression in knockout cells (Figure 5H). Since DMT1 and Zip14 both can mediate the cellular uptake of metal ions, the high expression of Zip14 in knockout cells may be a complement to the lack of DMT1. Its elevation after iron treatment in wild-type cells may be due to the decreased expression of DMT1, which affected the absorption of other ions [38,39,44]. In knockout cells, its slight reduction may be in response to the iron treatment. These results supported that Zip14 may play a role in iron transport in intestinal cells. Several reports showed that the expression of Zip14 is relatively high in the intestine [38,45], but there have been few reports on its role in the intestine up until now. Here, the results of our experiments may provide some clues for further explorations and future studies.

## 5. Conclusions

The iron transport and storage from Fe-Gly in intestinal cells was affected by the knockout of DMT1 as well as FeSO<sub>4</sub>, which indicated that Fe-Gly was probably mainly transported into the intestine cells via DMT1 like FeSO<sub>4</sub>. Zip14 may play a certain role in intestinal iron transport.

**Author Contributions:** Conceptualization: X.Y. and J.F.; Methodology: X.Y. and J.F.; Validation: L.C., H.D., and Y.Z.; Formal analysis: X.Y. and L.C.; Investigation: X.Y.; Resources: J.F.; Data Curation: H.D.; Writing—Original Draft Preparation: X.Y.; Writing—Review and Editing: L.C. and J.F.; Visualization: X.Y.; Supervision: J.F.; Project Administration: J.F.; Funding Acquisition: J.F.

**Funding:** This research was funded by the National Natural Science Foundation of China (No.31772607 and 31472102) and Zhejiang Provincial Key R & D Project (2019C02051).

Acknowledgments: The authors would like to thank Shenglin Fang and Zhao Zhuo for their suggestions on the experimental method and would also like to thank Genloci Biotechnologies Inc. (Nanjing, China) for providing technical support for cell knockout.

Conflicts of Interest: The authors declare no conflict of interest.

#### References

- 1. Matthias, W.H.; Martina, U.M.; Bruno, G.; Clara, C. Two to Tango: Regulation of Mammalian Iron Metabolism. *Cell* **2010**, *142*, 24–38.
- 2. Martina, U.M.; Stefano, R.; Matthias, W.H.; Bruno, G. A Red Carpet for Iron Metabolism. *Cell* **2017**, *168*, 344–361.
- 3. Camaschella, C. Iron-deficiency anemia. N. Engl. J. Med. 2015, 373, 485–486. [CrossRef] [PubMed]

- 4. Li, Y.; Yang, W.; Dong, D.; Jiang, S.; Yang, Z.; Wang, Y. Effect of different sources and levels of iron in the diet of sows on iron status in neonatal pigs. *Anim. Nutr.* **2018**, *4*, 197–202. [CrossRef] [PubMed]
- Creech, B.L.; Spears, J.W.; Flowers, W.L.; Hill, G.M.; Lloyd, K.E.; Armstrong, T.A.; Engle, T.E. Effect of dietary trace mineral concentration and source (inorganic vs. chelated) on performance, mineral status, and fecal mineral excretion in pigs from weaning through finishing. *J. Anim. Sci.* 2004, *82*, 2140–2147. [CrossRef] [PubMed]
- 6. Antonio, P.; Christine, E.; Eugenia, V.; Paul, S.; Florentine, H.; Susan, F. Mechanisms of iron uptake from ferric phosphate nanoparticles in human intestinal Caco-2 cells. *Nutrients* **2017**, *9*, 359–372.
- Feng, J.; Ma, W.Q.; Xu, Z.R.; He, J.X.; Wang, Y.Z.; Liu, J.X. The effect of iron glycine chelate on tissue mineral levels, fecal mineral concentration, and liver antioxidant enzyme activity in weanling pigs. *Anim. Feed Sci. Technol.* 2009, *150*, 106–113. [CrossRef]
- Kwiecien, M.; Samolinska, W.; Bujanowicz-Haras, B. Effects of iron–glycine chelate on growth, carcass characteristic, liver mineral concentrations and haematological and biochemical blood parameters in broilers. *J. Anim. Physiol. Anim. Nutr.* 2015, *99*, 1184–1196. [CrossRef] [PubMed]
- 9. Chary, N.S.; Kamala, C.T.; Raj, D.S.S. Assessing risk of heavy metals from consuming food grown on sewage irrigated soils and food chain transfer. *Ecotox. Environ. Saf.* **2008**, *69*, 513–524. [CrossRef] [PubMed]
- 10. Feng, J.; Ma, W.Q.; Xu, Z.R.; Wang, Y.Z.; Liu, J.X. Effects of iron glycine chelate on growth, haematological and immunological characteristics in weaning pigs. *Anim. Feed Sci. Technol.* **2007**, *134*, 261–272. [CrossRef]
- Ma, W.Q.; Sun, H.; Zhou, Y.; Wu, J.; Feng, J. Effects of iron glycine chelate on growth, tissue mineral concentrations, fecal mineral excretion, and liver antioxidant enzyme activities in broilers. *Biol. Trace Elem. Res.* 2012, 149, 204–211. [CrossRef] [PubMed]
- Zhuo, Z.; Yu, X.; Li, S.; Fang, S.; Feng, J. Heme and non-heme iron on growth performances, blood parameters, tissue mineral concentration, and intestinal morphology of weanling pigs. *Biol. Trace Elem. Res.* 2018. [CrossRef] [PubMed]
- 13. Yu, B.; Huang, W.; Chiou, P.W. Bioavailability of iron from amino acid complex in weanling pigs. *Anim. Feed Sci. Technol.* **2000**, *86*, 39–52. [CrossRef]
- 14. Ashmead, H.D. Comparative Intestinal Absorption and subsequent metabolism of metal amino acid chelates and inorganic metal salts. *Biol. Trace Elem. Res.* **1993**, *445*, 306–319.
- 15. Liao, Z.C.; Guan, W.T.; Chen, F.; Hou, D.X.; Wang, C.X.; Lv, Y.T.; Qiao, H.Z.; Chen, J.; Han, J.H. Ferrous bisglycinate increased iron transportation through DMT1 and PepT1 in pig intestinal epithelial cells compared with ferrous sulphate. *J. Anim. Feed Sci.* **2014**, *23*, 153–159. [CrossRef]
- 16. Fernando, P.; Manuel, O.; Eva, H.; Dora, I.M.; Miguel, A.; Angélica, L.; Virginia, G. Iron bis-glycine chelate competes for the nonheme-iron absorption pathway. *Am. J. Clin. Nutr.* **2002**, *76*, 577–581.
- 17. Yeung, C.K.; Glahn, R.P.; Miller, D.D. Inhibition of Iron Uptake from Iron Salts and Chelates by Divalent Metal Cations in Intestinal Epithelial Cells. *J. Agric. Food Chem.* **2005**, *53*, 132–136. [CrossRef] [PubMed]
- Zhuo, Z.; Fang, S.; Yue, M.; Zhang, Y.; Feng, J. Kinetics absorption characteristics of ferrous glycinate in SD rats and its impact on the relevant transport protein. *Biol. Trace Elem. Res.* 2014, 158, 197–202. [CrossRef] [PubMed]
- Zhuo, Z.; Fang, S.; Hu, Q.; Huang, D.; Feng, J. Digital gene expression profiling analysis of duodenum transcriptomes in SD rats administered ferrous sulfate or ferrous glycine chelate by gavage. *Sci. Rep.* 2016, *6*, 37923. [CrossRef] [PubMed]
- 20. Fleming, M.D.; Trenor, C.C.; Su, M.A.; Foernzler, D.; Beier, D.R.; Dietrich, W.F.; Andrews, N.C. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. *Nat. Genet.* **1997**, *16*, 383–386. [CrossRef] [PubMed]
- Shawki, A.; Anthony, S.R.; Nose, Y.; Engevik, M.A.; Niespodzany, E.J.; Barrientos, T.; Öhrvik, H.; Worrell, R.T.; Thiele, D.J.; Mackenzie, B. Intestinal DMT1 is critical for iron absorption in the mouse but is not required for the absorption of copper or manganese. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2015, 309, 635–647. [CrossRef] [PubMed]
- 22. Gunshin, H.; Mackenzie, B.; Berger, U.V.; Gunshin, Y.; Romero, M.F.; Boron, W.F.; Nussberger, S.; Gollan, J.L.; Hediger, M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. *Nature* **1997**, *388*, 482–488. [CrossRef] [PubMed]
- 23. Evstatiev, R.; Gasche, C. Iron sensing and signalling. Gut 2012, 61, 933–952. [CrossRef] [PubMed]

- 24. Bart, J.C.; Twan, L.; Stefano, R. Targeting iron metabolism in drug discovery and delivery. *Nat. Rev. Drug Discov.* **2017**, *16*, 400–423.
- 25. Salahudeen, A.A.; Thompson, J.W.; Ruiz, J.C.; Ma, H.W.; Kinch, L.N.; Li, Q.; Grishin, N.V.; Bruick, R.K. An E3 ligase possessing an iron- responsive hemerythrin domain is a regulator of iron homeostasis. *Science* **2009**, 326, 722–726. [CrossRef] [PubMed]
- Vashisht, A.A.; Zumbrennen, K.B.; Huang, X.; Powers, D.N.; Durazo, A.; Sun, D.; Bhaskaran, N.; Persson, A.; Uhlen, M.; Sangfelt, O.; et al. Control of iron homeostasis by an iron-regulated ubiquitin ligase. *Science* 2009, 326, 718–721. [CrossRef] [PubMed]
- 27. Muckenthaler, M.U.; Galy, B.; Hentze, M.W. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. *Annu. Rev. Nutr.* 2008, *28*, 197–213. [CrossRef] [PubMed]
- Galy, B.; Ferring-Appel, D.; Kaden, S.; Gröne, H.J.; Hentze, M.W. Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. *Cell Metab.* 2008, 7, 79–85. [CrossRef] [PubMed]
- Sanchez, M.; Galy, B.; Schwanhaeusser, B.; Blake, J.; Bähr-Ivacevic, T.; Benes, V.; Selbach, M.; Muckenthaler, M.U.; Hentze, M.W. Iron regulatory protein-1 and -2: Transcriptome-wide definition of binding mRNAs and shaping of the cellular proteome by iron regulatory proteins. *Blood* 2011, *118*, 168–179. [CrossRef] [PubMed]
- Wilkinson, N.; Pantopoulos, K. The IRP/IRE system in vivo: Insights from mouse models. *Front. Pharmacol.* 2014, 5, 176. [CrossRef] [PubMed]
- 31. Anderson, S.A.; Nizzi, C.P.; Chang, Y.I.; Deck, K.M.; Schmidt, P.J.; Galy, B.; Damnernsawad, A.; Broman, A.T.; Kendziorski, C.; Hentze, M.W.; et al. The IRP1-HIF-2α axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. *Cell Metab.* **2013**, *17*, 282–290. [CrossRef] [PubMed]
- 32. Anderson, E.R.; Taylor, M.; Xue, X.; Ramakrishnan, S.K.; Martin, A.; Xie, L.; Bredell, B.X.; Gardenghi, S.; Rivella, S.; Shah, Y.M. Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 4922–4930. [CrossRef] [PubMed]
- 33. Anjali, N.; Julio, C.R.; Poorna, S.; Sudipa, G.-R.; Ruth, A.S.; Timothy, L.S.; Richard, K.B.; Caroline, C.P. Activation of the HIF prolyl hydroxylase by the iron chaperones PCBP1 and PCBP2. *Cell Metab.* **2011**, *14*, 647–657.
- 34. Shah, Y.M.; Matsubara, T.; Ito, S.; Yim, S.H.; Gonzalez, F.J. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. *Cell Metab.* **2009**, *9*, 152–164. [CrossRef] [PubMed]
- 35. Taylor, K.M.; Morgan, H.E.; Johnson, A.; Nicholson, R.I. Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. *FEBS Lett.* **2005**, *579*, 427–432. [CrossRef] [PubMed]
- 36. Zhao, N.; Gao, J.; Enns, C.A.; Knutson, M.D. ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. *J. Biol. Chem.* **2010**, *285*, 32141–32150. [CrossRef] [PubMed]
- Gao, J.; Zhao, N.; Knutson, M.D.; Enns, C.A. The hereditary hemo-chromatosis protein, HFE, inhibits iron uptake via down-regulation of Zip14 in HepG2 cells. *J. Biol. Chem.* 2008, 283, 21462–21468. [CrossRef] [PubMed]
- Liuzzi, J.P.; Aydemir, F.; Nam, H.; Knutson, M.D.; Cousins, R.J. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. *Proc. Natl. Acad. Sci. USA* 2006, 103, 13612–13617. [CrossRef] [PubMed]
- Pinilla-Tenas, J.J.; Sparkman, B.K.; Shawki, A.; Illing, A.C.; Mitchell, C.J.; Zhao, N.; Liuzzi, J.P.; Cousins, R.J.; Knutson, M.D.; Mackenzie, B. Zip14 is a complex broad-scope metal-ion transporter whose functional properties support roles in the cellular uptake of zinc and nontransferrin-bound iron. *Am. J. Physiol. Cell Physiol.* 2011, 301, 862–871. [CrossRef] [PubMed]
- 40. Supak, J.; Chia-Yu, W.; Richard, C.; Wei, Z.; Alan, C.; Thomas, B.; Jae-Sung, K.; Shintaro, H.; Toshiyuki, F.; Mitchell, D.K. SLC39A14 is required for the development of hepatocellular iron overload in murine models of hereditary hemochromatosis. *Cell Metab.* **2015**, *22*, 138–150.
- 41. Supak, J.; Adenike, A.; Elizabeth, P.; Ralf, W.; Shintaro, H.; Toshiyuki, F.; Genesys, G.; Jessica, S.; Armin, G.; Christopher, J.; et al. SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 1769–1778.

- 42. Aydemir, T.B.; Kim, M.; Kim, J.; Colon-Perez, L.M.; Banan, G.; Mareci, T.H.; Febo, M.; Cousins, R.J. Metal transporter Zip14 (Slc39a14) deletion in mice increases manganese deposition and produces neurotoxic signatures and diminished motor activity. *J. Neurosci.* **2017**, *37*, 5996–6006. [CrossRef] [PubMed]
- 43. Xin, Y.; Gao, H.; Wang, J.; Qiang, Y.; Imam, M.U.; Li, Y.; Wang, J.; Zhang, R.; Zhang, H.; Yu, Y.; et al. Manganese transporter Slc39a14 deficiency revealed its key role in maintaining manganese homeostasis in mice. *Cell Discov.* **2017**, *3*, 17025. [CrossRef] [PubMed]
- 44. Illing, A.C.; Shawki, A.; Cunningham, C.L.; Mackenzie, B. Substrate profile and metal-ion selectivity of human divalent metal-ion transporter-1. *J. Biol. Chem.* **2012**, *287*, 30485–30496. [CrossRef] [PubMed]
- 45. Wang, C.Y.; Jenkitkasemwong, S.; Duarte, S.; Sparkman, B.K.; Shawki, A.; Mackenzie, B.; Knutson, M.D. ZIP8 is an iron and zinc transporter whose cell- surface expression is up-regulated by cellular iron loading. *J. Biol. Chem.* **2012**, *287*, 34032–34043. [CrossRef] [PubMed]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).